#long-acting injectables

This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.

Researchers are trying to harness the power of certain antibodies as long-acting injectable forms of HIV treatment or PrEP.

One injection of the cloned antibody significantly reduced participants’ viral load in a recent advanced trial.

HIV-positive members of a recent study saw many upsides to getting injections of meds only every four or eight weeks.

A trial of long-acting cabotegravir injected every eight weeks is already under way among men who have sex with men and trans women.

A recent study tested the long-acting injectable antiretrovirals cabotegravir and Edurant (rilpivirine) given every four or eight weeks.

This is according to a recent survey of gay and bi men taking daily Truvada as PrEP.

Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

A trial of long-acting cabotegravir given every eight weeks found that it yielded adequate drug levels and was well tolerated.

Cabotegravir and rilpivirine combo shows promise as well-tolerated and effective antiretroviral regimen in a trial.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

Now that he’s on PRO-140, an experimental weekly injection, Sheen “is feeling fantastic.”

In an ongoing small trial, adding a biweekly infusion of ibalizumab has helped quite a few people on failing antiretroviral regimens.

The actor is still in the FDA trial of an injectable HIV med.

The global trial of 4,500 trans women and cis men who have sex with men will see whether cabotegravir prevents HIV as well as daily Truvada.